Physician profile
Sara T Wester
NPI 1730380445
$77,543.35
in general payments reported to CMS, 2019-2025
12 companies · $7,651 in 2025
The $7,651 reported for 2025 was more than what 88% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $9,918 · 2021: $12K · 2022: $6,503 · 2023: $9,113 · 2024: $6,071 · 2025: $7,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K · Honoraria: $8,674 · Food and Beverage: $697 · Travel and Lodging: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $13,438.47 |
| Honoraria | $8,674.00 |
| Food and Beverage | $696.81 |
| Travel and Lodging | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $63,507.69 | 2019-2023 | Tepezza |
| Amgen INC. | $8,822.73 | 2024-2025 | Tepezza |
| Argenx US, INC. | $4,800.00 | 2025 | |
| Mallinckrodt Enterprises LLC | $131.26 | 2019 | |
| Allergan, INC. | $83.70 | 2019 | |
| Ethicon US, LLC | $42.96 | 2025 | Vistaseal |
| Mallinckrodt Hospital Products INC. | $39.45 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $33.85 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $25.84 | 2023 | |
| Sun Pharmaceutical Industries INC. | $22.10 | 2024 | |
| Medtronic USA, INC. | $18.58 | 2020 | |
| Katalyst Surgical, LLC | $15.19 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Wester listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.